Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

150P - Assessing the inflammatory profile and microbiome dynamics in colorectal cancer patients pre- and post-chemotherapy

Date

27 Jun 2024

Session

Poster Display session

Presenters

Erika Ruiz

Citation

Annals of Oncology (2024) 35 (suppl_1): S1-S74. 10.1016/annonc/annonc1477

Authors

H. Williams1, E. Ruiz1, E. Fernandez-Figueroa2, J. Melchor-Ruan1, A. Hernandez-Guerrero1, J. Falcon-Martinez3, J. Argueta-Donohué4

Author affiliations

  • 1 INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico/MX
  • 2 INMEGEN - Instituto Nacional de Medicina Genomica, Ciudad de Mexico/MX
  • 3 medsci Institute, MexicoCity/MX
  • 4 Instituto Nacional de Psiquiatría Ramon de la Fuente, Mexico/MX

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 150P

Background

Systemic and intratumoral inflammation in patients with Colorectal Carcinoma (CRC) has been directly linked to disease prognosis. Analyzing the interaction of interleukins, intratumoral lymphocytic infiltrates, tumor microenvironment, and microbiota is essential for understanding the pathogenesis and progression of the disease.

Methods

We conducted comprehensive analyses on 32 patients with CRC. Before treatment, we gathered primary tumor tissue and tissue samples from another site in the colon. Also, blood samples were collected before and after chemotherapy to analyze an inflammatory panel (IL-6, IL-10, IL-1,β CXCL-8, CASP-1, TLR2, DUSP-1, TNF-α). We obtained 15 fecal samples before treatment and 26 samples post-treatment to assess the diversity and abundance of microbiota.

Results

All 32 patients underwent chemotherapy. The median age was 49 years, 56% were female, 81.2% had left-sided CRC, and 71.9% presented with stage IV disease. Comparing tumor tissue versus non-tumor tissue samples, we noted a higher concentration of IL-6 (p 0.001) in the tumor. Post-chemotherapy, we observed a decrease in TNFα (p 0.04) in serum and a reduction in the expression of inflammatory genes IL-10 (p 0.005) and NRLP-1 (p 0.03) in peripheral blood cells. Notably, in the 11 paired pre- and post-treatment fecal samples, we found no changes in the diversity indices in the microbiome. The phylum Firmicutes remained the most abundant and were unaffected by systemic treatment. Interestingly, no lactobacillus species were detected in the fecal samples.

Conclusions

Interleukins and inflammatory genes are elevated in patients with CRC before systemic treatment. Inflammation is higher at the tumor site compared to healthy colonic tissue. Following chemotherapy, we found a decrease in interleukins and pro-inflammatory genes and discordant expression between plasma and peripheral blood cells. Interestingly, systemic treatment did not alter microbiome diversity in our patients. Understanding the interplay between inflammation and changes in microbiota could serve as a crucial foundation for future research endeavors.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.